Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


With VERTIS SITA2 On Board, Merck Eyes Broad Initial Approval For Ertugliflozin

Executive Summary

In an interview at the European Association for the Study of Diabetes meeting, Merck exec Sam Engel explains the rationale behind the clinical trial strategy for the SGLT-2 inhibitor ertugliflozin, as it gears up with partner Pfizer for filings by the end of this year.

You may also be interested in...

Keeping Track: US FDA Accepts Ertugliflozin, Extends Reviews Of Abaloparatide, New Keytruda Claim

The latest drug development news and highlights from our FDA Performance Tracker.

ADA: Diabetes Duo Merck & Pfizer Report Positive PhIII Data For Investigational SGLT-2

Merck & Co. Inc. and Pfizer Inc.'s investigational oral SGLT-2 inhibitor, ertugliflozin, has met its primary endpoints in two Phase III studies in type 2 diabetes patients – now the pair are continuing development with an 8,000 patient cardiovascular (CV) outcomes trial and plan to file the drug in US by the year end.

Januvia Gains Another Boost With FDA Warnings for Onglyza, Nesina

Heart failure worries could limit use of AstraZeneca and Takeda products, and their relabeling can only help Merck's market leader.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts